Results 211 to 220 of about 879,906 (340)
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
Development and external validation of a prognostic nomogram for event-free survival in resectable non-small cell lung cancer after neoadjuvant chemoimmunotherapy. [PDF]
Qu L +5 more
europepmc +1 more source
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Staging Laparoscopy in High-Risk Gastric Cancer: A Decade of Real-World Evidence and Therapeutic Impact from a Tertiary Referral Center. [PDF]
Cossu A +7 more
europepmc +1 more source
Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken +7 more
wiley +1 more source
A comprehensive review of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): staging, techniques, and future directions. [PDF]
Fiore C, Ayasa LA, Murn M, Swenson K.
europepmc +1 more source
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Urachal adenocarcinoma: a case report and literature review. [PDF]
Kostara K +4 more
europepmc +1 more source

